1 study found for:    NCT00390221
Show Display Options
Rank Status Study
1 Active, not recruiting Safety and Efficacy Study of Daclizumab HYP to Treat Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-remitting
Interventions: Drug: daclizumab HYP;   Other: placebo

Indicates status has not been verified in more than two years